Another breakthrough of ADCs in breast cancer
The FDA has recently approved Enhertu (trastuzumab deruxtecan), the antibody-drug conjugate (ADC) of AstraZeneca and Daiichi Sankyo for patients with unresectable or metastatic HER2-positive breast cancer following one prior anti-HER2 therapy, either in the metastatic phase or in the early-stage setting. With this latest authorization, observers have suggested that Enhertu is likely to replace Kadcyla, the first-generation ADC, to treat HER2-positive breast cancer. ACROBiosystems has developed a range of products to meet your needs at every stage of your ADC development journey.